A股異動 | 金城醫藥漲近7% 丁二磺酸腺苷蛋氨酸通過CDE審批
格隆匯2月10日丨金城醫藥(300233.SZ)盤中漲6.95%,報33.1元,總市值128億元。金城醫藥2月9日晚間公吿,全資子公司金城生物提交的“丁二磺酸腺苷蛋氨酸”非無菌原料藥註冊申請通過了國家藥監局藥品審評中心(CDE)審批。腺苷蛋氨酸是存在於人體所有組織和體液中的一種生理活性分子,在臨牀上主要適用於妊娠期肝內膽汁淤積;適用於肝硬化前和肝硬化所致肝內膽汁淤積。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.